Medigen Vaccine Biologics (6547) — Cash Flow Reinvestment Rate
Medigen Vaccine Biologics (6547) has a Cash Flow Reinvestment Rate of 3.00x as of December 2025, reinvesting NT$303.54 Million (capex NT$3.54 Million plus investments NT$300.00 Million) from operating cash flow of NT$101.08 Million. Check Medigen Vaccine Biologics (6547) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Medigen Vaccine Biologics Cash Flow Reinvestment Rate (2015–2024)
Historical reinvestment intensity for Medigen Vaccine Biologics across 3 annual periods. Explore cash flow to debt ratio of Medigen Vaccine Biologics to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Medigen Vaccine Biologics (2015–2024)
Year-by-year capital reinvestment analysis for Medigen Vaccine Biologics. For live market cap and broader valuation context, see 6547 company net worth.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 26.64x | NT$1.09 Billion | NT$40.75 Million | NT$34.98 Million | ▲ +1419.1% |
| 2021 | 1.75x | NT$1.02 Billion | NT$579.89 Million | NT$134.97 Million | ▼ -17.1% |
| 2015 | 2.11x | NT$457.15 Million | NT$216.26 Million | NT$457.15 Million | — |